🇺🇸 FDA
Pipeline program

SPD489 20 mg

SPD489-207

Phase 2 small_molecule completed

Quick answer

SPD489 20 mg for Sleep Deprivation is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Sleep Deprivation
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials